Merck KGaA, long troubled by pipeline setbacks, said it's back on track thanks to some high-profile partnerships and a particular focus on immuno-oncology. Speaking to Reuters, Luciano Rossetti, head of R&D at the company's Serono division, said Merck KGaA has "more than enough critical mass in oncology" after signing deals with Pfizer ($PFE) and Threshold Pharmaceuticals ($THLD), part of the German drugmaker's plans to bolster its pipeline as the top-selling Rebif loses ground to new competitors. "We see people who want to work with us in R&D," Rossetti said. "This wasn't true a few years ago." More